Stereochemistry | ACHIRAL |
Molecular Formula | C6H6ClN |
Molecular Weight | 127.572 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=CC=C(Cl)C=C1
InChI
InChIKey=QSNSCYSYFYORTR-UHFFFAOYSA-N
InChI=1S/C6H6ClN/c7-5-1-3-6(8)4-2-5/h1-4H,8H2
Molecular Formula | C6H6ClN |
Molecular Weight | 127.572 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
4-Chloroaniline (4-ClA) is a chlorinated aromatic amine that is formed as an intermediate during the microbial decomposition of phenylurea and phenylcarbamate. The formation of various oligomers by polymerization of 4-ClA with guaiacol in an aqueous solution containing oxidoreductases has been reported. 4-Chloroaniline is used as an intermediate in the production of
a number of products, including agricultural chemicals,
azo dyes and pigments, cosmetics, and pharmaceutical
products. Reactive metabolites of 4-Chloroaniline bind covalently to
haemoglobin and to proteins of liver and kidney. In
humans, haemoglobin adducts are detectable as early as
30 min after accidental exposure, with a maximum level
at 3 h. Repeated exposure to 4-Chloroaniline leads to cyanosis and
methaemoglobinaemia, followed by effects in blood,
liver, spleen, and kidneys, manifested as changes in
haematological parameters, splenomegaly, and moderate
to heavy haemosiderosis in spleen, liver, and kidney,
partially accompanied by extramedullary haematopoiesis. The marketing and use of products containing 4-Chloroaniline based
azo dyes were banned by the European
Union (EU) (EC, 2000).
CNS Activity
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
The lowest-observed-adverse effect
levels (LOAELs; no-observed-effect levels, or
NOELs, are not derivable) for a significant increase in
methaemoglobin levels in rats and mice are, respectively,
5 and 7.5 mg/kg body weight per day for a 13-
week oral administration of PCA by gavage (5 days/
week) and 2 mg/kg body weight per day for rats
administered PCA by gavage (5 days/week) at 26, 52,
78, and 103 weeks` exposure. Fibrotic changes of the
spleen were observed in male rats, with a LOAEL of
2 mg/kg body weight per day, and hyperplasia of bone
marrow was observed in female rats, with a LOAEL of
6 mg/kg body weight per day (103-week gavage).
Route of Administration:
Oral